|
Delayed
Australian S.E.
03:21:13 09/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.3300 AUD | 0.00% |
|
-7.04% | -49.23% |
Company Valuation: Recce Pharmaceuticals Ltd
Data adjusted to current consolidation scope
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 158.1 | 111.4 | 122.4 | 83.63 | 117.1 | 100.9 | - |
| Change | - | -29.54% | 9.86% | -31.67% | 40.05% | -13.84% | - |
| Enterprise Value (EV) 1 | 158.1 | 113 | 126.8 | 73.18 | 114.4 | 129.2 | 115.1 |
| Change | - | -28.55% | 12.25% | -42.29% | 56.36% | 12.88% | -10.89% |
| P/E | -14.1x | -8.31x | -6.02x | -3.21x | -7.83x | -3.3x | 17.4x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0.4x | -0.2x | 0.34x | 0.2x | -0x | -0x |
| Capitalization / Revenue | - | 25.8x | 23.4x | 10.9x | 11.8x | 14x | 4.1x |
| EV / Revenue | - | 26.2x | 24.2x | 9.5x | 11.5x | 17.9x | 4.68x |
| EV / EBITDA | - | -8.83x | -7.69x | -3.69x | -8.8x | -4.92x | 13.1x |
| EV / EBIT | - | -8.9x | -7.53x | -3.63x | -8.6x | -4.85x | 13.2x |
| EV / FCF | - | -8.88x | -9.64x | -3.58x | -11.5x | -11.2x | 18.9x |
| FCF Yield | - | -11.3% | -10.4% | -28% | -8.7% | -8.9% | 5.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.0631 | -0.0752 | -0.0997 | -0.0904 | -0.0517 | -0.1 | 0.019 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | 4.311 | 5.236 | 7.705 | 9.939 | 7.2 | 24.6 |
| EBITDA 1 | - | -12.8 | -16.49 | -19.81 | -13 | -26.26 | 8.8 |
| EBIT 1 | - | -12.69 | -16.83 | -20.17 | -13.3 | -26.65 | 8.7 |
| Net income 1 | -10.99 | -13.08 | -17.66 | -21.43 | -14.96 | -29.4 | 6.1 |
| Net Debt 1 | - | 1.562 | 4.415 | -10.45 | -2.694 | 28.26 | 14.2 |
| Reference price 2 | 0.8900 | 0.6250 | 0.6000 | 0.2900 | 0.4050 | 0.3300 | 0.3300 |
| Nbr of stocks (in thousands) | 177,647 | 178,254 | 203,987 | 288,372 | 289,183 | 305,770 | - |
| Announcement Date | 31/08/22 | 31/08/23 | 30/08/24 | 29/08/25 | 31/08/26 | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.3x | 17.94x | -4.92x | - | 69.39M | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.52x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.94x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.75x | 7.3x | 13.55x | 2.19% | 249B | |
| -39.18x | 7.28x | 45.82x | 1.98% | 207B | |
| Average | 26.46x | 8.31x | 18.58x | 2.04% | 417.98B | |
| Weighted average by Cap. | 35.67x | 8.55x | 21.86x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RCE Stock
- Valuation Recce Pharmaceuticals Ltd
Select your edition
All financial news and data tailored to specific country editions
